Drug Profile
Research programme: globoid cell leukodystrophy therapy - Takeda
Alternative Names: HGT-2610Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Shire
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Globoid cell leukodystrophy
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 18 Nov 2008 Preclinical trials in Globoid cell leukodystrophy in United Kingdom (Parenteral)